Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03285412
Title CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital

estrogen-receptor positive breast cancer



Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.